Your prominent trainers
Dipl. Chem. Martin Blüggel
Protagen Protein Services, Germany
Chief Executive Officer
Martin Blüggel is an expert for peptide and protein analysis, mass spectrometry and bioinformatics for protein analysis and proteomics. He is author of more than 35 scientific publications and has presented state of the art analytical methods to the Biotechnology Working Party (BWP, EMA) and Paul Ehrlich Institute (PEI). He became member of the extended Board of the EAPB (European Association of Pharma Biotechnology) in 2009. He holds a diploma in Chemistry for his research in protein chemistry combined with mass spectrometric methods for protein structure analysis. As a co-founder of Protagen in 1997 Martin Blüggel set up the business in Protagen´s Protein Services Unit serving over 100 international clients as CRO to support the development of protein therapeutics from early phases of discovery, production to GMP release testing. He has supervised biosimilar comparability studies and protein characterization for a range of 15 top originator molecules. Martin Blüggel was holding the position of Chief Operating Officer of Protagen since 2002 and Executive Vice President Protein Services since 2009. Since 2013 he is the CEO of Protagen Protein Services.
Dr. Robert E. Zoubek
Granzer Regulatory Consulting
& Services, Germany
Dr. Robert E. Zoubek is an expert in drug development, manufacturing, and analytics as well as regulatory affairs. Until he joined GR C&S as Senoir Consultant Robert worked in several positions at Formycon (Germany) and GlycoForm (UK). As Director Scientific Affairs he led Formycon's drug product development and analytical services and advised numerous clients on their development strategies. Another focus was Formycon´s Biosimilar portfolio. In other roles he was responsible on the CMC activities of the partnered Biologics programs and led the GMP-certified Quality Control laboratories. Robert earned the PhD from the University of Erlangen- Nuremberg for his research on the wound-healing peptide Thymosin beta 4 and he was awarded Master of Business Administration from the University of Manchester which was rated by Forbes as the 5th best business school worldwide. He also holds a MSc from the University of Munich. Today, he a Senior Consultant with Granzer Regulatory Consulting & Services.
DI Markus Roucka
Vela Labs, Austria
COO & Business Development
Markus started his career in the biotechnical laboratories of Biomin, Austria as Lab technician in the R&D department. He was responsible for fermentation and QC processes of the products. After more than four years he studied medical and pharmaceutical biotechnology at the University of Applied Science IMC Krems. For his Master thesis Markus went to the Netherlands and studied the effect of the TRIA L-ligand in combination with Bortezomib on NSCLC. He joined Vela laboratories 2008. After eight years as Head of Laboratory & assay development his current position is now COO and Business development.
Prof. Dr. Johannes Buchner
Technische Universität München,
Dept. Of Chemistry
After attaining his PhD in biochemistry in 1991, the author worked at the National Institute of Health in Bethesda, USA. Since1998, he holds a chair at the department of chemistry at the Technische Universität München. From 2003 to 2006, he was dean of the department. His field of research is protein science and specifically the mechanistic analysis of protein folding and stability as well as the machinery of cellular protein folding.